ARCHIVES

ODAC Votes Against Cell Therapeutics Agent; Requires ChemGenex To Develop Diagnostic.

This article is from The Cancer Letter archive.

Vol. 36 No. 13 | April 9, 2010

Download PDF Visit The Full Archive

Related Articles

NCI To Fund 160 P01s FY91, About same As Last Year; Considering New ‘Interactive’ R01

June 21, 1991

Nexavar Phase III Trial Fails To Meet Primary Endpoint

June 29, 2012

UT System Launches Probe of Submission Of Controversial MD Anderson Grant

June 8, 2012

DCE Board Delays Decision On New Collaborative Groups In Chemoprevention

November 30, 1984

NCI “Leadership Vacuum” Deepened?

December 22, 1994

Novartis Begins Study Of Femara And Zometa In Postmenopausal Early Breast Cancer

December 27, 2002